Symtuza

Darunavir contains a sulfa component, so use with caution in people with severe sulfa allergies. Side effects most commonly reported in studies include diarrhea (9%), rash (8%), nausea (6%), fatigue (4%), headache (3%), abdominal discomfort (2%), and flatulence (2%). While very rare (in less than 0.4% of those taking it), severe rash, accompanied in some cases by fever and/or elevations of AST/ALT (liver enzymes), can be life-threatening. Seek medical attention immediately. Data associate TAF with weight gain. Observational cohort studies reported an association between some PIs (including darunavir taken with ritonavir) and an increased risk of cardiovascular (CV) events. Data on darunavir + cobicistat are too limited to make these conclusions. With PIs, there can be increased bleeding in hemophiliacs. Cobicistat can cause a small, reversible increase in serum creatinine (SCr, which decreases estimated creatinine clearance) within the first few weeks of treatment without affecting glomerular filtration (the process by which the kidneys filter the blood; see Tybost for more information). While cobicistat does not affect actual kidney function, its effect on SCr can make monitoring of impaired kidney function more difficult or less accurate. However, people experiencing a confirmed increase in serum creatinine of greater than 0.4 mg/dL from baseline should be closely monitored for renal safety. Serum phosphorus in people with or at risk for kidney impairment should also be monitored. Prior to initiation, people should be tested for hepatitis B virus (HBV) infection. Severe exacerbations of hepatitis B have been reported in people co-infected with HBV who have discontinued Symtuza (due to elimination of the emtricitabine and TAF components, which also treat hepatitis B). Monitor liver enzymes closely in people co-infected with HBV and, if appropriate, initiation of anti-hepatitis B therapy may be warranted upon Symtuza discontinuation. Call your health care provider right away if you develop any of the following signs or symptoms of hepatitis: yellowing of the skin or whites of the eyes; dark or tea-colored urine; pale-colored bowel movements; nausea or vomiting; loss of appetite; or pain, aching, or tenderness on the right side below the ribs.

Do not take with alfuzosin, carbamazepine, dexamethasone, dronedarone, ergot derivatives, ivabradine, triazolam, oral midazolam, lomitapide, lurasidone, naloxegol, phenobarbital, phenytoin, pimozide, Revatio, sildenafil (Viagra, Revatio, and generics), simvastatin, lovastatin, St. John’s wort, ranolazine, or rifampin. Monitor for lack of virologic response when eslicarbazepine or oxcarbazepine is necessary. Not recommended to be taken with avanafil, ciclesonide, dabigatran etexilate (in renal impairment), everolimus, Intelence, irinotecan, mometasone, rifabutin, rifapentine, rivaroxaban, salmeterol, ticagrelor, triamcinolone, or voriconazole. Beclomethasone, prednisolone, and prednisone as alternative corticosteroids may be considered, particularly for long-term use. Atorvastatin and rosuvastatin dose should not exceed 20 mg daily. Clinical monitoring is recommended with drospirenone, due to potential for hyperkalemia. Apixaban (Eliquis) dose may need to be adjusted. Do not take with colchicine if there is kidney or liver impairment. The dose of colchicine will need to be adjusted. Initiation or dose adjustments of insulin or oral hypoglycemic medications may be required for some individuals. Cannot be taken with Zepatier. Based on the mechanism of action, drug interactions with other hepatitis C medications are probably similar to the interactions with Prezcobix + Descovy. Not intended to be taken with other HIV medications, unless prescribed that way. Tell your provider or pharmacist about all medications, herbals, and supplements you are taking or thinking of taking, prescribed or not, as there are other drug interactions that are not listed here.

A darunavir-based regimen is the only initiation treatment recommended by HHS for people who have used Apretude (CAB-LA for PrEP) when resistance data has yet to come back (rapid ART). That’s because viral mutations conferring drug resistance to INSTIs like long-acting cabotegravir (found in Apretude and in Cabenuva) have been observed. CAB-LA stays in the body a very long time and drug levels may be too low to prevent infection and therefore may select for resistant virus. The other “clinical situations” mentioned in the HHS recommendation refers to people with adherence problems on their current HIV treatment. Symtuza is not the same as Prezcobix + Descovy, because Symtuza contains a lower dose of TAF than Descovy. A benefit of the PIs is their high genetic barrier to developing drug resistance. While medical providers may hate to say it out loud, this means greater forgiveness of missed doses; missing a dose here and there is never advisable but does happen. As such, a PI-based regimen such as Symtuza suits some people who may have trouble with the near-perfect drug adherence required of HIV treatment. In fact, the FDA allowed Janssen to advertise Symtuza as “help[s] protect against resistance.” Darunavir-containing regimens had stronger evidence supporting their use than do regimens containing atazanavir (another PI on the market). Pregnant individuals can voluntarily enroll in the Antiretroviral Pregnancy Registry through their provider; GO TO apregistry.com.

Dr. Melanie Thompson:

Symtuza, a 4-drug protease inhibitor-based STR, is not recommended for initial therapy for most people with HIV due to the presence of the booster cobicistat, which causes many drug interactions. It is, however, now recommended for initial therapy for non-pregnant persons who acquired HIV following cabotegravir PrEP (Apretude) and who wish to start therapy before an INSTI genotype is available, or whose virus has resistance to INSTIs. This is based on the long “PK-tail” for cabotegravir which could select for INSTI-resistant viruses when the drug is present at levels too low to prevent infection. Symtuza is not recommended in pregnancy because lower levels of cobicistat and also darunavir in the second and third trimesters can decrease antiviral efficacy. If you are pregnant and on Symtuza, talk with your HIV care provider about changing therapy. A recent study showed no benefit on weight in people changing from an INSTI-containing regimen to Symtuza.

For most people, the multitude of drug-drug interactions with COBI make unboosted INSTI regimens preferable. Possible side effects of Symtuza include diarrhea, nausea, abdominal discomfort, headache, rash and, less frequently, liver toxicity. Symtuza also is associated with elevated triglycerides and cholesterol (LDL and total.) A large observational study found an association between darunavir and cardiovascular disease. The average wholesale cost for Symtuza is the highest of all STRs and higher even than maintenance doses of Cabenuva.

Activist Joey Wynn:

Once a powerful option with a great profile against resistance, today this combination does not hold up against newer meds. This is mainly due to the booster, which increases almost every medication in the bloodstream; not a good look in 2024.